M&A Deal Summary

Elekta Acquires CMS

On January 8, 2008, Elekta acquired medical products company CMS for 75M USD

Acquisition Highlights
  • This is Elekta’s 1st transaction in the Medical Products sector.
  • This is Elekta’s 2nd largest (disclosed) transaction.
  • This is Elekta’s 3rd transaction in the United States.
  • This is Elekta’s 1st transaction in Missouri.

M&A Deal Summary

Date 2008-01-08
Target CMS
Sector Medical Products
Buyer(s) Elekta
Deal Type Add-on Acquisition
Deal Value 75M USD

Target

CMS

St. Louis, Missouri, United States
CMS, Inc. is a provider in the development and support of radiation treatment planning and workflow management solutions.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Elekta

Stockholm, Sweden

Category Company
Founded 1972
Sector Medical Products
Employees4,536
Revenue 18.0B SEK (2025)
DESCRIPTION

Elekta is an international medical-technology Group, providing highly advanced clinical solutions for high precision radiation treatment of cancer and for non- or minimally invasive treatment of brain disorders. Clinical solutions include, among others, Leksell Gamma Knife® for non-invasive treatment of brain surgery and Elekta Synergy for image-guided radiation therapy (IGRT) as well as associated software systems. Elekta was founded in 1972 and is based in Stockholm, Sweden.


DEAL STATS #
Overall 4 of 9
Sector: Medical Products M&A 1 of 2
Type: Add-on Acquisition M&A Deals 4 of 9
State: Missouri M&A 1 of 1
Country: United States M&A 3 of 3
Year: 2008 M&A 1 of 1
Size (of disclosed) 2 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2007-03-23 3D Line Medical Systems S.r.l

Milan, Michigan, United States

3D Line Medical Systems S.r.l develops and supplies hardware and software for linear accelerator.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2010-05-31 Resonant Medical

Montreal, Quebec, Canada

Resonant Medical, Inc. is a developer of revolutionary clinical solutions that are safe and gentle for the patient while increasing the accuracy and precision of radiotherapy cancer care.

Buy CA$30M